Download PDF
Semin Neurol 2017; 37(05): 538-545
DOI: 10.1055/s-0037-1607278
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Advances in Imaging Multiple Sclerosis

Antje Bischof
1   Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California
2   Department of Neurology and Immunology Clinic, University Hospital Basel, Basel, Switzerland
,
Eduardo Caverzasi
1   Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California
,
Christian Cordano
1   Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California
,
Stephen L. Hauser
1   Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California
,
Roland G. Henry
1   Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California
› Author Affiliations
Further Information

Publication History

Publication Date:
05 December 2017 (online)

    Permissions and Reprints

Abstract

Neuroimaging has emerged as a powerful technology that has enabled visualization of the impact of multiple sclerosis (MS) on the central nervous system in vivo with unprecedented precision. It has played a crucial role in disentangling the chronology of inflammation and neurodegeneration, developing and understanding mechanisms of novel therapeutics, and diagnosing and monitoring the disease in the clinical setting. However, challenges pertaining to the limited resolution, lack of specificity, inherent technological biases, and processing of increasingly big datasets have hindered comprehensive insights into the pathology underlying disability.

Here, we review the advances in neuroimaging for MS that have moved the field forward in recent years by addressing the above-mentioned issues, thereby enhancing our knowledge of this yet enigmatic disease. We discuss complementary imaging technologies, including magnetic resonance imaging, positron emission tomography, and optical coherence tomography, the most recent tool in the MS imaging armamentarium that holds promise to act as a surrogate of pathological changes in the central nervous system in a more easily accessible way.

Keywords

multiple sclerosis - magnetic resonance imaging - positron emission tomography - optical coherence tomography - atrophy
 

  • References

  • 1 Polman CH, Reingold SC, Banwell B. , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (02) 292-302
    CrossrefPubMedGoogle Scholar
  • 2 Gafson A, Giovannoni G, Hawkes CH. The diagnostic criteria for multiple sclerosis: from Charcot to McDonald. Mult Scler Relat Disord 2012; 1 (01) 9-14
    CrossrefPubMedGoogle Scholar
  • 3 Solomon AJ, Klein EP, Bourdette D. “Undiagnosing” multiple sclerosis: the challenge of misdiagnosis in MS. Neurology 2012; 78 (24) 1986-1991
    CrossrefPubMedGoogle Scholar
  • 4 Hammond KE, Lupo JM, Xu D. , et al. Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases. Neuroimage 2008; 39 (04) 1682-1692
    CrossrefPubMedGoogle Scholar
  • 5 Hammond KE, Metcalf M, Carvajal L. , et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008; 64 (06) 707-713
    CrossrefPubMedGoogle Scholar
  • 6 Bagnato F, Hametner S, Pennell D. , et al. 7T MRI-histologic correlation study of low specific absorption rate T2-weighted GRASE Sequences in the detection of white matter involvement in multiple sclerosis. J Neuroimaging 2015; 25 (03) 370-378
    CrossrefPubMedGoogle Scholar
  • 7 Dal-Bianco A, Grabner G, Kronnerwetter C. , et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol 2017; 133 (01) 25-42
    CrossrefPubMedGoogle Scholar
  • 8 Absinta M, Sati P, Gaitán MI. , et al. Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol 2013; 74 (05) 669-678
    CrossrefPubMedGoogle Scholar
  • 9 Absinta M, Sati P, Schindler M. , et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest 2016; 126 (07) 2597-2609
    CrossrefPubMedGoogle Scholar
  • 10 Frischer JM, Weigand SD, Guo Y. , et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 2015; 78 (05) 710-721
    CrossrefPubMedGoogle Scholar
  • 11 Park E, Gallezot JD, Delgadillo A. , et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging 2015; 42 (07) 1081-1092
    CrossrefPubMedGoogle Scholar
  • 12 Vowinckel E, Reutens D, Becher B. , et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 1997; 50 (02) 345-353
    CrossrefPubMedGoogle Scholar
  • 13 Oh U, Fujita M, Ikonomidou VN. , et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol 2011; 6 (03) 354-361
    CrossrefPubMedGoogle Scholar
  • 14 Banati RB, Newcombe J, Gunn RN. , et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123 (Pt 11): 2321-2337
    CrossrefPubMedGoogle Scholar
  • 15 Debruyne JC, Versijpt J, Van Laere KJ. , et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003; 10 (03) 257-264
    CrossrefPubMedGoogle Scholar
  • 16 Rissanen E, Tuisku J, Rokka J. , et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med 2014; 55 (06) 939-944
    CrossrefPubMedGoogle Scholar
  • 17 Politis M, Giannetti P, Su P. , et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 2012; 79 (06) 523-530
    CrossrefPubMedGoogle Scholar
  • 18 Cosenza-Nashat M, Zhao ML, Suh HS. , et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009; 35 (03) 306-328
    CrossrefPubMedGoogle Scholar
  • 19 Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain 2017; 140 (07) 1900-1913
    CrossrefPubMedGoogle Scholar
  • 20 Herder V, Iskandar CD, Kegler K. , et al. Dynamic changes of microglia/macrophage M1 and M2 polarization in Theiler's murine encephalomyelitis. Brain Pathol 2015; 25 (06) 712-723
    CrossrefPubMedGoogle Scholar
  • 21 Miron VE, Boyd A, Zhao JW. , et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013; 16 (09) 1211-1218
    CrossrefPubMedGoogle Scholar
  • 22 Filippi M, Rocca MA, Ciccarelli O. , et al; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016; 15 (03) 292-303
    CrossrefPubMedGoogle Scholar
  • 23 Traboulsee A, Simon JH, Stone L. , et al. Revised recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol 2016; 37 (03) 394-401
    CrossrefPubMedGoogle Scholar
  • 24 Sati P, Oh J, Constable RT. , et al; NAIMS Cooperative. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 2016; 12 (12) 714-722
    CrossrefPubMedGoogle Scholar
  • 25 Lummel N, Boeckh-Behrens T, Schoepf V, Burke M, Brückmann H, Linn J. Presence of a central vein within white matter lesions on susceptibility weighted imaging: a specific finding for multiple sclerosis?. Neuroradiology 2011; 53 (05) 311-317
    CrossrefPubMedGoogle Scholar
  • 26 Samaraweera AP, Clarke MA, Whitehead A. , et al. The central vein sign in multiple sclerosis lesions is present irrespective of the T2* sequence at 3 T. J Neuroimaging 2017; 27 (01) 114-121
    CrossrefPubMedGoogle Scholar
  • 27 Magliozzi R, Howell O, Vora A. , et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (Pt 4): 1089-1104
    PubMedGoogle Scholar
  • 28 Lucchinetti CF, Popescu BF, Bunyan RF. , et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365 (23) 2188-2197
    CrossrefPubMedGoogle Scholar
  • 29 Absinta M, Vuolo L, Rao A. , et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015; 85 (01) 18-28
    CrossrefPubMedGoogle Scholar
  • 30 Absinta M, Cortese IC, Vuolo L. , et al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology 2017; 88 (15) 1439-1444
    CrossrefPubMedGoogle Scholar
  • 31 Dousset V, Grossman RI, Ramer KN. , et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 1992; 182 (02) 483-491
    CrossrefPubMedGoogle Scholar
  • 32 Campi A, Filippi M, Comi G, Scotti G, Gerevini S, Dousset V. Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis. Neuroradiology 1996; 38 (02) 115-119
    CrossrefPubMedGoogle Scholar
  • 33 Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43 (06) 809-814
    CrossrefPubMedGoogle Scholar
  • 34 Crespy L, Zaaraoui W, Lemaire M. , et al. Prevalence of grey matter pathology in early multiple sclerosis assessed by magnetization transfer ratio imaging. PLoS One 2011; 6 (09) e24969
    CrossrefPubMedGoogle Scholar
  • 35 Brown JW, Pardini M, Brownlee WJ. , et al. An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis. Brain 2017; 140 (Pt 2): 387-398
    CrossrefPubMedGoogle Scholar
  • 36 Rudko DA, Derakhshan M, Maranzano J, Nakamura K, Arnold DL, Narayanan S. Delineation of cortical pathology in multiple sclerosis using multi-surface magnetization transfer ratio imaging. Neuroimage Clin 2016; 12: 858-868
    CrossrefPubMedGoogle Scholar
  • 37 Kearney H, Yiannakas MC, Samson RS, Wheeler-Kingshott CA, Ciccarelli O, Miller DH. Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord. Brain 2014; 137 (Pt 9): 2456-2468
    CrossrefPubMedGoogle Scholar
  • 38 Schmierer K, Tozer DJ, Scaravilli F. , et al. Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging 2007; 26 (01) 41-51
    CrossrefPubMedGoogle Scholar
  • 39 Taso M, Girard OM, Duhamel G. , et al. Tract-specific and age-related variations of the spinal cord microstructure: a multi-parametric MRI study using diffusion tensor imaging (DTI) and inhomogeneous magnetization transfer (ihMT). NMR Biomed 2016; 29 (06) 817-832
    CrossrefPubMedGoogle Scholar
  • 40 Lema A, Bishop C, Malik O. , et al. A comparison of magnetization transfer methods to assess brain and cervical cord microstructure in multiple sclerosis. J Neuroimaging 2017; 27 (02) 221-226
    CrossrefPubMedGoogle Scholar
  • 41 Cercignani M, Symms MR, Schmierer K. , et al. Three-dimensional quantitative magnetisation transfer imaging of the human brain. Neuroimage 2005; 27 (02) 436-441
    CrossrefPubMedGoogle Scholar
  • 42 Pierpaoli C, Barnett A, Pajevic S. , et al. Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage 2001; 13 (6 Pt 1): 1174-1185
    CrossrefPubMedGoogle Scholar
  • 43 Wheeler-Kingshott CA, Cercignani M. About “axial” and “radial” diffusivities. Magn Reson Med 2009; 61 (05) 1255-1260
    CrossrefPubMedGoogle Scholar
  • 44 Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 2012; 61 (04) 1000-1016
    CrossrefPubMedGoogle Scholar
  • 45 By S, Xu J, Box BA, Bagnato FR, Smith SA. Application and evaluation of NODDI in the cervical spinal cord of multiple sclerosis patients. Neuroimage Clin 2017; 15: 333-342
    CrossrefPubMedGoogle Scholar
  • 46 Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A 1993; 90 (12) 5662-5666
    CrossrefPubMedGoogle Scholar
  • 47 Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998; 11 (06) 266-272
    CrossrefPubMedGoogle Scholar
  • 48 Cawley N, Solanky BS, Muhlert N. , et al. Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain 2015; 138 (Pt 9): 2584-2595
    CrossrefPubMedGoogle Scholar
  • 49 Choi IY, Lee P, Hughes AJ, Denney DR, Lynch SG. Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis. Mult Scler 2017; 23 (07) 956-962
    CrossrefPubMedGoogle Scholar
  • 50 MacKay A, Whittall K, Adler J, Li D, Paty D, Graeb D. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994; 31 (06) 673-677
    CrossrefPubMedGoogle Scholar
  • 51 Laule C, Leung E, Lis DK. , et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler 2006; 12 (06) 747-753
    CrossrefPubMedGoogle Scholar
  • 52 Kitzler HH, Su J, Zeineh M. , et al. Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI. Neuroimage 2012; 59 (03) 2670-2677
    CrossrefPubMedGoogle Scholar
  • 53 Kolind S, Matthews L, Johansen-Berg H. , et al. Myelin water imaging reflects clinical variability in multiple sclerosis. Neuroimage 2012; 60 (01) 263-270
    CrossrefPubMedGoogle Scholar
  • 54 Vargas WS, Monohan E, Pandya S. , et al. Measuring longitudinal myelin water fraction in new multiple sclerosis lesions. Neuroimage Clin 2015; 9: 369-375
    CrossrefPubMedGoogle Scholar
  • 55 Lansley J, Mataix-Cols D, Grau M, Radua J, Sastre-Garriga J. Localized grey matter Atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci Biobehav Rev 2013; 37 (05) 819-830
    CrossrefPubMedGoogle Scholar
  • 56 Bishop CA, Newbould RD, Lee JS. , et al. Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions. Neuroimage Clin 2016; 13: 9-15
    PubMedGoogle Scholar
  • 57 Vidal-Jordana A, Sastre-Garriga J, Pareto D. , et al. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Mult Scler 2017; (Epub ahead of print) DOI: 10.1177/1352458517707070.
    CrossrefPubMedGoogle Scholar
  • 58 Kappos L, De Stefano N, Freedman MS. , et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 2016; 22 (10) 1297-1305
    CrossrefPubMedGoogle Scholar
  • 59 Schlaeger R, Papinutto N, Panara V. , et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 2014; 76 (04) 568-580
    CrossrefPubMedGoogle Scholar
  • 60 Daams M, Weiler F, Steenwijk MD. , et al. Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability. Mult Scler 2014; 20 (14) 1860-1865
    CrossrefPubMedGoogle Scholar
  • 61 Kearney H, Rocca MA, Valsasina P. , et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler 2014; 20 (01) 72-80
    CrossrefPubMedGoogle Scholar
  • 62 Cawley N, Tur C, Prados F. , et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Mult Scler 2017; (Epub ahead of print) DOI: 10.1177/1352458517709954.
    CrossrefPubMedGoogle Scholar
  • 63 Lukas C, Knol DL, Sombekke MH. , et al. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015; 86 (04) 410-418
    CrossrefPubMedGoogle Scholar
  • 64 De Stefano N, Stromillo ML, Giorgio A. , et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87 (01) 93-99
    CrossrefPubMedGoogle Scholar
  • 65 Schlaeger R, Papinutto N, Zhu AH. , et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol 2015; 72 (08) 897-904
    CrossrefPubMedGoogle Scholar
  • 66 Bagci AM, Shahidi M, Ansari R, Blair M, Blair NP, Zelkha R. Thickness profiles of retinal layers by optical coherence tomography image segmentation. Am J Ophthalmol 2008; 146 (05) 679-687
    CrossrefPubMedGoogle Scholar
  • 67 Podoleanu AG, Rosen RB. Combinations of techniques in imaging the retina with high resolution. Prog Retin Eye Res 2008; 27 (04) 464-499
    CrossrefPubMedGoogle Scholar
  • 68 Frohman EM, Costello F, Stüve O. , et al. Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol 2008; 65 (01) 26-35
    PubMedGoogle Scholar
  • 69 Grazioli E, Zivadinov R, Weinstock-Guttman B. , et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci 2008; 268 (1–2): 12-17
    CrossrefPubMedGoogle Scholar
  • 70 Henderson AP, Trip SA, Schlottmann PG. , et al. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain 2008; 131 (Pt 1): 277-287
    PubMedGoogle Scholar
  • 71 Ratchford JN, Saidha S, Sotirchos ES. , et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 2013; 80 (01) 47-54
    CrossrefPubMedGoogle Scholar
  • 72 Dörr J, Wernecke KD, Bock M. , et al. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS One 2011; 6 (04) e18132
    CrossrefPubMedGoogle Scholar
  • 73 Saidha S, Al-Louzi O, Ratchford JN. , et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. Ann Neurol 2015; 78 (05) 801-813
    CrossrefPubMedGoogle Scholar
  • 74 Martinez-Lapiscina EH, Arnow S, Wilson JA. , et al; IMSVISUAL consortium. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol 2016; 15 (06) 574-584
    CrossrefPubMedGoogle Scholar
  • 75 Saidha S, Sotirchos ES, Ibrahim MA. , et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012; 11 (11) 963-972
    CrossrefPubMedGoogle Scholar
  • 76 Knier B, Schmidt P, Aly L. , et al. Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain 2016; (Epub ahead of print) DOI: 10.1093/brain/aww219.
    CrossrefPubMedGoogle Scholar
  • 77 Button J, Al-Louzi O, Lang A. , et al. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: a retrospective study. Neurology 2017; 88 (06) 525-532
    CrossrefPubMedGoogle Scholar
  • 78 Klein A, Ghosh SS, Bao FS. , et al. Mindboggling morphometry of human brains. PLOS Comput Biol 2017; 13 (02) e1005350
    CrossrefPubMedGoogle Scholar
  • 79 Rovira À, Wattjes MP, Tintoré M. , et al; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 2015; 11 (08) 471-482
    CrossrefPubMedGoogle Scholar
  • 80 Wattjes MP, Rovira À, Miller D. , et al; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11 (10) 597-606
    CrossrefPubMedGoogle Scholar
  • 81 Cotton F, Kremer S, Hannoun S, Vukusic S, Dousset V. ; Imaging Working Group of the Observatoire Français de la Sclérose en Plaques. OFSEP, a nationwide cohort of people with multiple sclerosis: consensus minimal MRI protocol. J Neuroradiol 2015; 42 (03) 133-140
    CrossrefPubMedGoogle Scholar
  • 82 Keshavan A, Paul F, Beyer MK. , et al; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG. Power estimation for non-standardized multisite studies. Neuroimage 2016; 134: 281-294
    CrossrefPubMedGoogle Scholar
  • 83 Biberacher V, Schmidt P, Keshavan A. , et al. Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. Neuroimage 2016; 142: 188-197
    CrossrefPubMedGoogle Scholar
  • 84 Rocca MA, Battaglini M, Benedict RH. , et al. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology 2017; 88 (04) 403-413
    CrossrefPubMedGoogle Scholar
  • 85 Giannetti P, Politis M, Su P. , et al. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain 2015; 138 (Pt 1): 110-119
    CrossrefPubMedGoogle Scholar
  • 86 Endres CJ, Pomper MG, James M. , et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009; 50 (08) 1276-1282
    CrossrefPubMedGoogle Scholar
  • 87 Takano A, Piehl F, Hillert J. , et al. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Res 2013; 3 (01) 30
    CrossrefPubMedGoogle Scholar
  • 88 Colasanti A, Guo Q, Muhlert N. , et al. In vivo assessment of brain white matter inflammation in multiple sclerosis with (18)F-PBR111 PET. J Nucl Med 2014; 55 (07) 1112-1118
    CrossrefPubMedGoogle Scholar
  • 89 Gerwien H, Hermann S, Zhang X. , et al. Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. Sci Transl Med 2016; 8 (364) 364ra152
    CrossrefPubMedGoogle Scholar
  • 90 Dickens AM, Vainio S, Marjamäki P. , et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med 2014; 55 (03) 466-472
    CrossrefPubMedGoogle Scholar
  • 91 Mohan S, Verma A, Lim CC, Hui F, Kumar S. Lipid resonance on in vivo proton mr spectroscopy: value of other metabolites in differential diagnosis. Neuroradiol J 2010; 23 (03) 269-278
    CrossrefPubMedGoogle Scholar
  • 92 Muhlert N, Atzori M, De Vita E. , et al. Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. J Neurol Neurosurg Psychiatry 2014; 85 (08) 833-839
    CrossrefPubMedGoogle Scholar
  • 93 Kirov II, Liu S, Tal A. , et al. Proton MR spectroscopy of lesion evolution in multiple sclerosis: steady-state metabolism and its relationship to conventional imaging. Hum Brain Mapp 2017; 38 (08) 4047-4063
    CrossrefPubMedGoogle Scholar
  • 94 Llufriu S, Kornak J, Ratiney H. , et al. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol 2014; 71 (07) 840-847
    CrossrefPubMedGoogle Scholar
  • 95 Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990; 40 (11) 1764-1769
    CrossrefPubMedGoogle Scholar
  • 96 Hattingen E, Magerkurth J, Pilatus U, Hübers A, Wahl M, Ziemann U. Combined (1)H and (31)P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis. NMR Biomed 2011; 24 (05) 536-546
    CrossrefPubMedGoogle Scholar